Chenodeoxycholic Acid PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
474-25-9
Molecular formula
C24H40O4
Molecular weight
392.57 g/mol
Drug class
Primary bile acidfarnesoid X receptor (FXR) ligand and bile-acid metabolic substrate
Mechanism of action
Acts as an endogenous bile acid that facilitates intestinal absorption of dietary fats and fat-soluble vitamins. It also activates FXR and regulates bile-acid synthesis and transport. Therapeutic effects in cerebrotendinous xanthomatosis (CTX) involve replacement of deficient bile-acid feedback and suppression of abnormal bile-acid precursor synthesis.
Indications / reported uses
Treatment of cerebrotendinous xanthomatosis (CTX) in adults and eligible paediatric patients using authorised chenodeoxycholic acid products; other gallstone-dissolution uses are historical or product-specific and should not be assumed
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Chenodeoxycholic Acid PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Chenodeoxycholic Acid Permitted Daily Exposure (PDE) report (the Chenodeoxycholic Acid PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Chenodeoxycholic Acid Occupational Exposure Limit (OEL) report (the Chenodeoxycholic Acid OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.